King’s College London researchers discovered that parts of our DNA once thought to be “junk” can actually help destroy cancer ...
Discover a study on PARP inhibitors in prostate cancer, revealing survival benefits for patients with BRCA1/2 alterations.
The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.
LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity ...
University of Colorado Cancer Center member Matthew Sikora, Ph.D., is a national leader in research into an understudied subtype of breast cancer that's on the rise in American women, is often more ...
Chemotherapy may soon take a backseat. Experts say targeted therapies—drugs that attack cancer at the genetic level—are ...
Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION ®, a tumor-activated oncology delivery platform, today announced the ...
When pembrolizumab was added to paclitaxel with or without bevacizumab in platinum-resistant ovarian cancer, significant ...
Nanoform Finland Plc | Press Release | October 27, 2025 at 09:10:00 EET Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced a partnership ...
The data, first presented at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting, showed that the phase 3 ...
In the study, researchers molecularly screened nearly 2,000 cancer patients and matched 14 percent into a study arm.
A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback